Epithalon: Clinical Guide for Prescribing Practices
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for its effects on telomerase activation and telomere elongation. Developed by Russian gerontologist Vladimir Khavinson, it has been researched primarily in the context of aging and longevity, though clinical evidence remains limited.
Also Known As
How Epithalon Works
Epithalon (Ala-Glu-Asp-Gly) activates telomerase reverse transcriptase (hTERT) gene expression, enabling the ribonucleoprotein telomerase complex to synthesize TTAGGG telomeric repeat sequences at chromosome ends [1]. This counteracts the progressive telomere shortening that occurs with each cell division (the Hayflick limit) [2]. Additionally, Epithalon stimulates pineal gland function and melatonin secretion through regulation of the circadian neuroendocrine axis, which may contribute to its observed effects on sleep architecture and neuroendocrine aging markers [3].
Clinical Evidence
Khavinson's group published a 15-year observational study showing that peptide bioregulators including Epithalon reduced mortality by 28% compared to controls in an elderly cohort [1]. In vitro studies demonstrate that Epithalon reactivates telomerase in human somatic cells and elongates telomeres in fibroblast cultures [2]. A 2003 study in Biogerontology reported that Epithalon reduced spontaneous tumor incidence in SHR mice while extending lifespan [3]. These findings have not been replicated in Western peer-reviewed randomized controlled trials, and the available evidence consists primarily of research from a single group [1][2].
Clinical Uses
Patient Selection and Screening
Candidates are longevity-focused patients seeking proactive cellular aging interventions, ideally those with documented short telomere length (via commercially available telomere testing) [2]. Absolute contraindication in patients with active malignancy or significant cancer history, as telomerase activation is a hallmark of cancer cell immortalization [3]. Caution in patients with strong family history of cancer. Best suited for patients who understand the experimental nature of this intervention and accept the limited Western evidence base [1]. Patients should be enrolled in regular cancer screening programs while on Epithalon protocols.
Dosing and Administration
Standard protocol: 5 to 10 mg subcutaneously daily for 10 to 20 consecutive days, repeated once or twice annually (cyclical dosing) [1]. Some protocols use 10 mg daily for 10 days every 6 months. The cyclical (pulsed) approach is based on Khavinson's original research design and is theorized to provide telomerase activation without sustained stimulation that could theoretically promote malignant transformation [3]. Injection site should be rotated. No loading or maintenance dosing between cycles; the therapeutic effect is proposed to persist between treatment windows [1].
Route: Subcutaneous injection, intravenous
Protocol notes: Typically administered via subcutaneous injection in cyclical protocols (10mg daily for 10-20 days, repeated 1-2 times per year). Protocols are based on limited clinical data.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Epithalon's appeal lies in the longevity-focused, high-net-worth patient demographic willing to invest in cutting-edge anti-aging interventions [1]. The cyclical protocol (10 to 20 day treatments, 1 to 2 times yearly) creates concentrated revenue events rather than ongoing prescriptions. Practices can bundle Epithalon cycles with full longevity assessments including telomere testing [2], which validates the treatment rationale and generates additional lab revenue. Its positioning as a premium, science-forward intervention supports higher per-patient pricing in concierge and executive health settings.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Epithalon through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What is the evidence for epithalon's anti-aging effects?
What are the safety concerns with telomerase activation?
References
- Khavinson VKh, et al. Peptide bioregulator telomerase activator in the treatment of age-related pathology. Bull Exp Biol Med. 2003;135(Suppl 7):73-77.
- Khavinson V, et al. Mechanisms of biological activity of Epithalon peptide on telomerase function and telomere length. Biol Bull Rev. 2020;10:137-145.
- Anisimov VN, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202.
- Khavinson VKh, Malinin VV. Gerontological aspects of genome peptide regulation. Basel: Karger; 2005.
Related Peptides in Metabolic & Longevity
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Epithalon Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Epithalon Through Karpa